Experts and Doctors on nogalamycin in United States

Summary

Locale: United States
Topic: nogalamycin

Top Publications

  1. Buckner J, Edmonson J, Ingle J, Schaid D. Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure. Am J Clin Oncol. 1989;12:384-6 pubmed
    ..We conclude that menogaril does not appear to be useful at this dose and schedule in the treatment of metastatic sarcomas despite the use of near maximal doses in patients with no prior chemotherapy exposure. ..
  2. Long H, Schaid D, Schutt A, Ingle J, Loprinzi C, Edmonson J. Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy. Am J Clin Oncol. 1988;11:524-7 pubmed
    ..Failure to respond to menogaril does not preclude response to subsequent treatment with doxorubicin. ..
  3. Welch J, Rauscher F, Beerman T. Targeting DNA-binding drugs to sequence-specific transcription factor.DNA complexes. Differential effects of intercalating and minor groove binding drugs. J Biol Chem. 1994;269:31051-8 pubmed
    ..The A/T-directed minor groove binding drugs, while inhibiting hTBP at submicromolar concentrations, had no effect on either EGR1 or NIL2A. ..
  4. White C, Heidenreich O, Nordheim A, Beerman T. Evaluation of the effectiveness of DNA-binding drugs to inhibit transcription using the c-fos serum response element as a target. Biochemistry. 2000;39:12262-73 pubmed
    ..These systematic analyses provide insight into how drug and transcription factor binding characteristics are related to drugs' effectiveness in inhibiting gene expression. ..
  5. Peng R, VanNieuwenhze M. A model study for constructing the DEF-benzoxocin ring system of menogaril and nogalamycin via a reductive Heck cyclization. Org Lett. 2012;14:1962-5 pubmed publisher
    ..A novel reductive Heck cyclization approach was developed in order to construct a model DEF-benzoxocin ring system that is present in nogalamycin, menogaril, and related anthracycline antitumor antibiotics. ..
  6. Chiang S, Welch J, Rauscher F, Beerman T. Effect of DNA-binding drugs on early growth response factor-1 and TATA box-binding protein complex formation with the herpes simplex virus latency promoter. J Biol Chem. 1996;271:23999-4004 pubmed
    ..TFIIA.DNA complex and restored the EGR1.DNA complex. We conclude that the binding motif and sequence preference of DNA-interactive drugs are manifested in their ability to inhibit the transcription factor-DNA complexes. ..
  7. Larson E, Drummond J. Human mismatch repair and G*T mismatch binding by hMutSalpha in vitro is inhibited by adriamycin, actinomycin D, and nogalamycin. J Biol Chem. 2001;276:9775-83 pubmed
    ..These data suggest that adriamycin interacts with the mismatch repair pathway through a mechanism distinct from the manner by which covalent DNA lesions are processed. ..